

UCSF Adult Inpatient Susceptibility Data (Gram-Negatives)¹

R-testing not applicable to organism and should be considered resistant, **CFPM**-cefepime, **CIP**-ciprofloxacin, **CTAZ**-ceftazidime, **CTRX**-ceftriaxone, **ERTA**-ertapenem, **IMI**-imipenem-cilastatin, **MER**-meropenem, **P/T**-piperacillin-tazobactam, **TOB**-tobramycin
Total isolates include floor isolates and ICU isolates from Parnassus, MB Adult, and MZ
Reported as % susceptible, tested from all sites except as indicated

Organism	Total Isolates	CFPM	CIP	CTAZ	CTRX	ERTA	IMI/MER ₂	P/T	TOB
Weighted average	2261	86	74	84	62 (77) ₃	78 (97) ₃	96 ₄	85	89
<i>Citrobacter freundii</i>	57	98	84	N/A	N/A	98	96	N/A	87
<i>Enterobacter cloacae</i>	151	88	90	N/A	N/A	89	94	N/A	92
<i>Escherichia coli</i>	867	83	64	87	76	99	99	91	86
<i>Klebsiella aerogenes</i>	66	98	95	N/A	N/A	98	96	N/A	96
<i>Klebsiella oxytoca</i>	110	82	79	83	73	95	96	80	79
<i>Klebsiella pneumoniae</i>	318	83	74	83	77	96	98	81	84
<i>Proteus mirabilis</i>	164	93	74	98	90	100	98	98	86
<i>Pseudomonas aeruginosa</i>	443	85	79	85	N/A	N/A	89	76	97
<i>Serratia marcescens</i>	85	100	92	100	97	98	96	98	95

¹Adult inpatient susceptibilities include data from 4/1/2023-3/31/2024; ²Reflects % susceptibility for imipenem-cilastatin in all situations except for *Proteus mirabilis*, where % susceptibility for meropenem (non-urine isolates, 67 total isolates) is reported; ³Parentheses excludes Pseudomonas isolates; ⁴Weighted average excludes 164 *Proteus mirabilis* isolates tested against imipenem

UCSF Adult Inpatient Susceptibility Data (Gram-Positives)¹

R-testing not applicable to organism and should be considered resistant, **AMP**-ampicillin, **CLIN**-clindamycin, **CTRX**-ceftriaxone, **DAP**-daptomycin, **DOX**-doxycycline, **LZD**-linezolid, **NAF**-nafcillin, **PCN**-penicillin G, **T/S**-trimethoprim/sulfamethoxazole, **VANC**-vancomycin
 Total isolates include floor isolates and ICU isolates from Parnassus, MB Adult, and MZ
 Reported as % susceptible, tested from all sites except as indicated

Organism	Total Isolates	AMP/PCN ²	CLIN	CTRX	DAP	DOX	LZD	NAF	T/S	VANC
<i>Staphylococcus aureus</i>	833	N/A	73	N/A	100	88	100	72	96	100
MSSA	609	N/A	77	N/A	100	93	100	99	97	100
MRSA	234	N/A	62	N/A	100	72	100	N/A	94	99
<i>Staphylococcus epidermidis</i>	252	N/A	56	N/A	100	77	100	29	51	100
<i>Staphylococcus lugdunesis</i>	36	N/A	83	N/A	100	88	100	80	51	100
Viridans group streptococci ³	87	79	84	95		61				100
<i>Streptococcus mitis</i>	44	72	84	97		70				100
<i>Enterococcus faecalis</i>	281	99	N/A	N/A	100	27	100	N/A	N/A	97
<i>Enterococcus faecium</i>	169	14	N/A	N/A	98 ⁴	36	96	N/A	N/A	41

¹Adult inpatient susceptibilities include data from 4/1/2023-3/31/2024; ²Reflects ampicillin for *Enterococcus* spp & penicillin G for *Streptococcus* spp; ³Viridans group streptococci include *S. anginosus*, *S. constellatus*, *S. intermedius*, *S. milleri*, *S. mitis*, *S. mutans*, *S. oralis*, *S. parasanguinis*, *S. salivarius*, & *S. sobrinus*; ⁴Represents susceptible dose-dependent isolates only

UCSF Adult Outpatient Susceptibility Data: *S. aureus*¹

CLIN-clindamycin, **DOX**-doxycycline, **LZD**-linezolid, **NAF**-nafcillin, **T/S**-trimethoprim/sulfamethoxazole, **VANC**-vancomycin

Reported as % susceptible, tested from all sites except as indicated

Organism	Total Isolates	CLIN	DOX	LZD	NAF	T/S	VANC
<i>Staphylococcus aureus</i>	445	74	86	100	81	94	100
MSSA	371	76	88	100	100	97	100
MRSA	84	60	77	100	N/A	80	100

¹Adult outpatient susceptibilities include data from 4/1/2023-3/31/2024

UCSF Adult Outpatient Susceptibility Data: *E. coli* Urinary Isolates¹

AMP/SUL-ampicillin-sulbactam, **CIP**-ciprofloxacin, **CTRX**-ceftriaxone, **CZLN**-cefazolin, **NTF**-nitrofurantoin, **T/S**-trimethoprim-sulfamethoxazole

Reported as % susceptible, tested from urinary sites

Organism	Total Isolates	AMP/SUL ²	CIP	CTRX	CZLN ³	NTF	T/S
<i>Escherichia coli</i> , urine	852	67	76	91	90	97	74

¹Adult outpatient susceptibilities include data from 4/1/2023-3/31/2024; ²Surrogate test to predict oral amoxicillin/clavulanate; ³Surrogate test to predict oral agents cefdinir, cefpodoxime, cefprozil, cefuroxime, and cephalexin when used for uncomplicated UTIs